ICOTF - iCo Therapeutics Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1083
-0.0104 (-8.76%)
At close: 12:46PM EDT
Stock chart is not supported by your current browser
Previous Close0.1187
Open0.1168
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1083 - 0.1168
52 Week Range0.0200 - 0.2040
Volume17,000
Avg. Volume48,073
Market Cap8.65M
Beta1.50
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile5 days ago

    iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B

    Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive pharmacokinetic secondary end point in its Phase 1 clinical study. Previously the Company reported that the study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects, including ...

  • Newsfile24 days ago

    iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study

    Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse ...

  • Newsfilelast month

    iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment

    Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study. Phase 1 Oral Amp B Clinical TrialThe Phase 1 Australian study is a randomized, double-masked, placebo-controlled, single dose ascending study to assess the safety, tolerability, and bioavailability of iCo-019 (Oral Amphotericin B). Subjects ...

  • Associated Press2 months ago

    Ico Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of less than 1 cent. In the final minutes of trading on Wednesday, the company's shares hit 2 cents. A year ago, they ...

  • Newsfile2 months ago

    iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial

    Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."Recently, we dosed our first subject with our novel Oral Amphotericin B (Oral AmpB) formulation. Strong recruitment has resulted in our dosing of all subjects in three of ...

  • Why iCo Therapeutics Inc’s (CVE:ICO) CEO Pay Matters To You
    Simply Wall St.3 months ago

    Why iCo Therapeutics Inc’s (CVE:ICO) CEO Pay Matters To You

    Leading iCo Therapeutics Inc (TSXV:ICO) as the CEO, Andrew Rae took the company to a valuation of CA$2.53M. Understanding how CEOs are incentivised to run and grow their company isRead More...

  • Newsfile3 months ago

    iCo Therapeutics Announces Year End 2017 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - April 24, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").2017 Financial & Operational HighlightsDuring the year, we advanced our oral formulation of Amphotericin B completing our 14-day GLP toxicology study which revealed that oral administration of Amphotericin ...

  • Newsfile3 months ago

    iCo Therapeutics Announces Major Milestone - Dosing of First Patient for its Oral Amphotericin B Phase 1 Clinical Study

    Vancouver, British Columbia--(Newsfile Corp. - April 18, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has dosed the first patient in its Phase 1 clinical study for Oral Amphotericin B. "Dosing our first patient is a major milestone for iCo Therapeutics and the oral Amphotericin B program" stated Andrew Rae, President and CEO of iCo Therapeutics ...

  • One Thing To Consider Before Buying iCo Therapeutics Inc (CVE:ICO)
    Simply Wall St.3 months ago

    One Thing To Consider Before Buying iCo Therapeutics Inc (CVE:ICO)

    If you are a shareholder in iCo Therapeutics Inc’s (TSXV:ICO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Who Really Owns iCo Therapeutics Inc (CVE:ICO)?
    Simply Wall St.5 months ago

    Who Really Owns iCo Therapeutics Inc (CVE:ICO)?

    I am going to take a deep dive into iCo Therapeutics Inc’s (TSXV:ICO) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...

  • Associated Press8 months ago

    Ico Therapeutics posts 3Q loss

    The Vancouver, British Columbia-based company said it had a loss of less than 1 cent on a per-share basis. In the final minutes of trading on Tuesday, the company's shares hit 3 cents. A year ago, they ...

  • Newsfile8 months ago

    iCo Therapeutics Announces Third Quarter 2017 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - November 28, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended September 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the quarter, we continued to advance our novel Oral Amphotericin B (Oral Amp B) candidate towards the clinic, and we are pleased that these efforts culminated in ...

  • Newsfile8 months ago

    IIROC Trade Resumption - iCo Therapeutics Inc.

    Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - Trading resumes in: Company: iCo Therapeutics Inc. TSX-V Symbol: ICO ...

  • Newsfile8 months ago

    iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study

    Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its recently formed subsidiary iCo Therapeutics Australia Pty Ltd., today announced that it has been granted ethics approval in Australia to conduct its proposed Phase 1 clinical study for Oral Amphotericin B. Amphotericin B is a well-known approved drug for the treatment of fungal and parasitic infections but the therapy is currently limited ...

  • Newsfile8 months ago

    IIROC Trade Halt - iCo Therapeutics Inc.

    Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - The following issues have been halted by IIROC: Company:  iCo Therapeutics Inc. TSX-V Symbol: ICO ...

  • What You Must Know About iCo Therapeutics Inc’s (TSXV:ICO) Risks
    Simply Wall St.10 months ago

    What You Must Know About iCo Therapeutics Inc’s (TSXV:ICO) Risks

    If you are a shareholder in iCo Therapeutics Inc’s (TSXV:ICO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Newsfile10 months ago

    iCo Therapeutics Announces Upcoming Presentations and Meetings

    Vancouver, British Columbia--(Newsfile Corp. - September 7, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced that it has been invited to present at the following upcoming conferences:19th Annual Rodman and Renshaw Global Investment Conference, New York, New YorkiCo is currently scheduled to present at the 19th Annual Rodman and Renshaw Global Investment Conference being held between September 10th and 12th, 2017 at the Lotte New York Palace Hotel, ...

  • Associated Press11 months ago

    Ico Therapeutics posts 2Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of less than 1 cent. In the final minutes of trading on Tuesday, the company's shares hit 4 cents. A year ago, they ...

  • Newsfile11 months ago

    iCo Therapeutics Announces Second Quarter 2017 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - August 29, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended June 30, 2017. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS")."During the quarter, we reported the results of our preclinical, 14-day, GLP toxicology study with our novel Oral Amphotericin B (Oral Amp B) candidate. We were pleased ...

  • Newsfile11 months ago

    iCo Therapeutics Inc. Approves Advance Notice Policy

    Vancouver, British Columbia--(Newsfile Corp. - August 4, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced that its board of directors has adopted an advance notice policy (the "Advance Notice Policy").The purpose of the Advance Notice Policy is to provide shareholders, directors and management of the Company with direction on the procedure for shareholder nomination of directors. The Advance Notice Policy is the framework by which the Company seeks to ...